^
Association details:
| Biomarker: | MAP2K1 mutation + TMB-H |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MAP2K1/2 and MAP3K14 as a prognostic biomarker on immunotherapy and correlated with immune infiltrates in melanoma.
Published date:
05/13/2020
Excerpt:
Results showed that MAP2K1/2 and MAP3K14 mutations were associated with an increased progression-free survival (PFS; HR, 0.42; 95% CI, 0.18-0.96; P = 0.0342) and a superior overall survival (OS; HR, 0.28; 95% CI, 0.09-0.90; P = 0.0227) in melanoma with significance at borderline level. TMB levels in melanoma patients with MAP2K1/2 and MAP3K14 mutations were higher than in wild-type patients (P = 0.007).
DOI:
10.1200/JCO.2020.38.15_suppl.e22104
